COMBINED ASSAY OF SERUM TUMOR ENZYME MARKERS IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA / 重庆医科大学学报

FDP/FIP (88.8%), respectively; (3) The diagnostic positivity of combination assay was 80.0% in low or negative AFP producing HCC, while 95.7% in those with elevated AFP. Our data suggested that the combination assay of serum tumor enzyme markers was valuable in the diagnosis of HCC, especially in low or negative AFP HCC patients